Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product ca...Show More
products_or_servicesInnovative therapies for inflammatory, rare and specialty diseases, and cancer, including small molecule inhibitors and antibody-drug conjugates.